Calquence

PreclinicalSmall molecule

IiOMEDICO AG

Calquence is one of 51 small molecule programs targeting Chronic Lymphocytic Leukemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Lymphocytic LeukemiaActive, not recruiting

Chronic Lymphocytic LeukemiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

367 competitors in Chronic Lymphocytic Leukemia

#DrugCompanyPhaseTrials

Rituxan

Venclexta

50 3

Gazyva

Roche

Phase 3

58 4

Calquence

AstraZeneca

Phase 3

23 5

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

42 6

Nipent

Pfizer

Phase 3

13 7

Brukinsa

BBeOne Medicines

Phase 3

15 8

Medrol

Pfizer

Phase 3

1 9

Adcetris

Pfizer

Phase 3

1 10

Beqalzi

BBeOne Medicines

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Lymphocytic Leukemia1 trial

Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO)

Active, not recruiting·IiOMEDICO AG··NCT05517265·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Calquence. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Calquence compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Calquence. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — iOMEDICO AG company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IiOMEDICO AG

Calquence

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Lymphocytic Leukemia1 trial

References

Drug Info

Quick Facts

Related News